Loading clinical trials...
Loading clinical trials...
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.
The primary purpose of this observational study is to assess the physician's clinical practice patterns while using VeriStrat testing in subjects with NSCLC whose tumors are epidermal growth factor receptor (EGFR) wild-type (negative) or have unknown EGFR mutational status. This study will also attempt to further validate that VeriStrat test results stratify subjects by clinical outcomes in the real world, uncontrolled clinical setting while exploring whether certain therapeutic approaches may yield opportunities for further study. Predictive tests that aid physician therapeutic decision making are critical for optimizing subject outcomes while minimizing toxicity and associated treatment costs. This study will provide data for the validation of immunotherapy tests currently being developed. Immunotherapy mechanisms are dependent upon the interactions between the tumor, tumor microenvironment, and the patient immune system. As such, a successful predictive test will reflect the complex interplay between tumor and host. The multivariate tests from Biodesix have the advantage of being able to assess this complex biology. The information gained from this research will not only guide the adoption of the VeriStrat test and inform medical decision making, including treatment choice, but will allow the validation of additional mass-spectrometry-based proteomic tests.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Oncology Specialties, PC; Clearview Cancer Institute
Huntsville, Alabama, United States
Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center
Tuscaloosa, Alabama, United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
St. Bernards Cancer Center Hematology / Oncology
Jonesboro, Arkansas, United States
Valley Medical Oncology Consultants
Pleasanton, California, United States
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, United States
Boca Raton Regional Hospital -Lynn Cancer Institute
Boca Raton, Florida, United States
Lake City Cancer Care, LLC
Lake City, Florida, United States
South Eastern Regional Medical Center
Newnan, Georgia, United States
Summit Cancer Care
Savannah, Georgia, United States
Start Date
April 4, 2016
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2025
Last Updated
September 19, 2025
5,006
ACTUAL participants
Lead Sponsor
Biodesix, Inc.
NCT06305754
NCT07190248
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07100080